Odontogenic tumors (TOs) consist of a group of heterogeneous lesions of varied clinical and histological behavior, derived from the epithelium, ectomesenchyma and/ or mesenchyma of the dental apparatus or its remnants. They range from tumor malformations (hamartomas) to benign neoplasms and metastatic malignancies. They are rare entities composing only 1% of the tumors of the maxillofacial region, making specific protocols and therapeutic guidelines not available. Early diagnosis and good therapeutic planning contribute to a better prognosis. Objectives: The objective of this study was to perform a retrospective clinical and pathological analysis of the TOs, in order to establish casuistry in our service. Methods: We performed a retrospective survey of the patients who developed TOs from 1980 and were treated in our institution. Clinicopathological data were collected from medical records with the aid of a standardized record for the study. Histopathological analysis of H&E slides was performed for histological confirmation of tumor types. Results: In this study, 73 patients who had OTs were analyzed. The age ranged from 2 to 78 years, with an average of 36.4 years. A total of 48 (65.75%) were female patients, and 25 (34.25%) were male patients. A total of 46 patients (63%) presented with involvement of the mandible. The maxilla was affected in 21 of the cases (28.76%). As for the histopathological report, 13 (17,80%) were ameloblastoma, 10 (13.69%) odontogenic tumor, eight (10.59%) odontogenic cyst without any other specification, four (5.47%) dendritic cysts, fibromas, two (2.74%) composite odontomas, one (1.37%) complex odontoma, and one mixed odontoma, one myxoma, one fibrous dysplasia with associated aneurysmal cyst, one cyst odontogenic calcifying, one fibro-odontoma, and 25 unspecified cases.
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Conclusion:
The collected samples added epidemiological data to the literature and covered the main histological subtypes of TOs, including some rare ones. The data contribute to international indexes and reinforce clinicopathological findings of these tumors. Wyrzykowski Medical Technology, James Gu Student, Ming Xie, MD; William Beaumont Hospital, Troy, MI Introduction: Partial thromboplastin time (PTT) is one of the most commonly used laboratory tests for evaluation of hemostasis. However, prolonged PTT can be paradoxical clinically, either due to bleeding disorder (factor deficiency) or thrombophilic situation (anticoagulation agents/inhibitors). It is crucial to understand the common etiologies for prolonged PTT in the interpretation of abnormal PTT results and the related patient management.
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Methods and Materials:
This study reviews the commonly used anticoagulation medications in patients with prolonged PTT and the possible etiologies for prolonged PTT in these patients. A total of 1,140 patients were identified with prolonged PTT at the coagulation laboratory at William Beaumont Hospital in Troy, Michigan, from August 2015 to April 2016. Electronic medical charts of these patients were reviewed for anticoagulation/antithrombotic medications, including warfarin, direct oral anticoagulants (apixaban, rivaroxaban and dabigatran, or direct oral anticoagulants [DOACs]), heparin, low molecular weight heparin (LMWH) and anti-platelet agents (aspirin, Plavix, prasugrel, and ticagrelor). Results: Among the 1,140 patients, 873 (76.6%) were receiving one or more anticoagulation medications at the time with prolonged PTT, and 267 (23.4%) patients had no anticoagulation medications. In patients receiving anticoagulation medications, the numbers of medications were as follows: 281 warfarin (32.2%), 232 DOACs (26.6%), 27 heparin/LMWH (3.1%), and 333 anti-platelet agents (38.1%). There were 390 (44.7%) patients receiving two or more anticoagulation medications, and the most common second anticoagulation medication was aspirin, seen in 376 patients (43.1%). Conclusion: In this study, the majority (76.6%) of patients with prolonged PTT were receiving one or more anticoagulation/antithrombotic medications. Nearly half (47.4%) of them received warfarin, heparin/LMWH, and/or DOACs, which are likely the causes of prolonged PTT. Anti-platelet agents were seen in another 29.2% of patients, indicative of thrombophilic condition in these patients. The remaining (23.4%) patients received no anticoagulation/antithrombotic medications, and the prolonged PTT may be an indication for the evaluation of possible underlying bleeding disorders. Introduction: Measurement of coagulation assay is pivotal all across in different specialties in field of medicine. We compared prothrombin time, activated prothrombin time and fibrinogen from fresh blood samples drawn into glass vs. plastic tubes. There was a recent recall of glass tubes nationwide from a leading manufacture. This type of situation imposes difficult scenario and put labs in a dilemma whether to use plastic tubes in place of glass tubes. Also the literature is extremely sparse in reference to the use of plastic tubes and shows inconsistence results. Hence, there is a need for further studies. To handle this scenario of the recall, the quality assurance project was performed at CMC Philadelphia VA Medical Center. Method: We collected 65 venous blood samples into 4.5 mL glass tubes and 2.7 mL plastic tubes from mix population patients with and without anticoagulant therapy. After centrifugation we used Diagnostic Stago instrument with Stago reagents for this testing. Mean and standard deviation (SD) were used to verify the adequacy of the analytic ranges in the study and to summarize results. Results: In our results, there was no statistically significance difference observed in prothrombin time, activated partial thromboplastin time, and fibrinogen results. We used Bland-Altman plot for determination of results comparison. Bland-Altman plot shows good correlation between two methods, and their regression shows excellent correlation of r values between 0.98 and 1.00. There is no indication of bias between the methods. Conclusion: Our study shows that the plastic tubes can be safely and successfully used for the coagulation studies in place of glass tubes. 
Objectives:
We have previously examined the effect of crizotonib (criz) and doxorubicin (dox) on cell lines of ALK+ anaplastic large cell lymphoma (ALCL), and found that while criz induces apoptosis, the effect is antagonized by dox. We also found that criz-induced apoptosis was associated with downregulation of the cell cycle check point modulator CDK2, which is required for transition from G1 into S phase. The current experiment examined cell cycle effects of the two drugs on the ALK+ ALCL cell line Karpas 299 (K299). Methods: K299 cells were incubated with slightly less than IC50 doses of each drug, alone and in combination, and compared to untreated controls. The cells were collected after six hours, suspended with PI/RNase staining solution, and acquired using a BD LSRFortessa (BD Biosciences, San Jose, CA) cell analyzer. Cell cycle analysis data were generated using FCS Express, version 5 (DeNovo Software, Los Angeles, CA) with the MultiCycle AV DNA analysis package.
Results: Criz showed marked decrease in S phase with increase in G1 phase compared to untreated cells, whereas both dox alone and in combination with criz showed mild increase in S phase with decrease in G1 phase compared to untreated cells. Conclusion: Results show that criz inhibits progression through cell cycle, while dox-treated cells progress through cell cycle. Cells treated with both drugs behave similarly to those with dox alone. These findings are consistent with doxorubicin antagonism of crizotinib at the level of the cell cycle in ALK+ ALCL (2010) (2011) (2012) (2013) (2014) (2015) . VTE events were objectively confirmed. Active GC was defined as biopsy-proven metastatic disease or on active chemotherapy. We defined stage as limited (Stage I-II) and advanced (stage III-IV). We used the four-level grading system of the American Joint Committee on Cancer to stratified adenocarcinoma (G1-G4). We stratified gastrointestinal stromal tumor into low and high grade based on their mitotic rate. To make twolevel and four-level grading systems comparable, adenocarcinoma was stratified into low (G1 and G2) and high (G3 and G4) grade. Continuous and categorical data are expressed by the median (interquartile range) and by percentages. We used SPSS version 23 to estimate the association of tumor grade with VTE and mortality using Cox proportional regression. Results: We included 106 patients who were predominantly men (64%), with a median age of 59 (52-65) years, adenocarcinoma (85%), and advanced disease (58%). The median follow-up was 22.6 months (9.8-42.6). The cumulative incidence of VTE at one year was 13%. The median time from diagnosis to VTE occurrence was 59 days (36-258). Tumor grade was not associated with a higher risk of VTE (univariate HR 0.60; 95% CI 0.19-1.84; P = .37) or mortality (univariate HR 1.09; 95% CI 0.64-1.86; P = .74). In multivariate analysis, after adjusting for BMI, stage, performance status, only obesity (HR 4.11; 95% CI 1.74-13.31; P = .18) and performance
